BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 11400152)

  • 1. Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart.
    Soini Y; Satta J; Määttä M; Autio-Harmainen H
    J Pathol; 2001 Jun; 194(2):225-31. PubMed ID: 11400152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
    Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
    Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between matrix metalloproteinases and tissue inhibitor of metalloproteinases in the wall of abdominal aortic aneurysms.
    Nishimura K; Ikebuchi M; Kanaoka Y; Ohgi S; Ueta E; Nanba E; Ito H
    Int Angiol; 2003 Sep; 22(3):229-38. PubMed ID: 14612849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy.
    Pritchard SC; Nicolson MC; Lloret C; McKay JA; Ross VG; Kerr KM; Murray GI; McLeod HL
    Oncol Rep; 2001; 8(2):421-4. PubMed ID: 11182067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma.
    Bramhall SR; Neoptolemos JP; Stamp GW; Lemoine NR
    J Pathol; 1997 Jul; 182(3):347-55. PubMed ID: 9349239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
    Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
    J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mRNA expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: potential role of TIMP1 as an adverse prognostic factor.
    Scrideli CA; Cortez MA; Yunes JA; Queiróz RG; Valera ET; da Mata JF; Toledo SR; Pavoni-Ferreira P; Lee ML; Petrilli AS; Brandalise SR; Tone LG
    Leuk Res; 2010 Jan; 34(1):32-7. PubMed ID: 19875168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma.
    Kallakury BV; Karikehalli S; Haholu A; Sheehan CE; Azumi N; Ross JS
    Clin Cancer Res; 2001 Oct; 7(10):3113-9. PubMed ID: 11595703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover.
    Phillips PA; McCarroll JA; Park S; Wu MJ; Pirola R; Korsten M; Wilson JS; Apte MV
    Gut; 2003 Feb; 52(2):275-82. PubMed ID: 12524413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas.
    Théret N; Musso O; Turlin B; Lotrian D; Bioulac-Sage P; Campion JP; Boudjéma K; Clément B
    Hepatology; 2001 Jul; 34(1):82-8. PubMed ID: 11431737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic AMP-regulated synthesis of the tissue inhibitors of metalloproteinases suppresses the invasive potential of the human fibrosarcoma cell line HT1080.
    Tanaka K; Iwamoto Y; Ito Y; Ishibashi T; Nakabeppu Y; Sekiguchi M; Sugioka Y
    Cancer Res; 1995 Jul; 55(13):2927-35. PubMed ID: 7796421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic expression of matrix metalloproteinases (MMP-2, -9 and -14) and the tissue inhibitors of MMPs (TIMP-1, -2 and -3) at the implantation site during tubal pregnancy.
    Bai SX; Wang YL; Qin L; Xiao ZJ; Herva R; Piao YS
    Reproduction; 2005 Jan; 129(1):103-13. PubMed ID: 15615902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.
    Määttä M; Soini Y; Liakka A; Autio-Harmainen H
    Clin Cancer Res; 2000 Jul; 6(7):2726-34. PubMed ID: 10914717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder.
    Staack A; Badendieck S; Schnorr D; Loening SA; Jung K
    BMC Urol; 2006 Aug; 6():19. PubMed ID: 16901349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of metalloproteinases and their tissue inhibitors in gingiva affected by hereditary gingival fibromatosis: analysis of three cases within a family.
    Gonçalves Lda R; Oliveira GA; Borojevic R; Otazu IB; Feres-Filho EJ
    J Periodontal Res; 2009 Dec; 44(6):714-7. PubMed ID: 19453853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MMP/TIMP imbalance in amniotic fluid during PROM: an indirect support for endogenous pathway to membrane rupture.
    Fortunato SJ; Menon R; Lombardi SJ
    J Perinat Med; 1999; 27(5):362-8. PubMed ID: 10642956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase expression in the ascending aorta and aortic valve.
    Wilton E; Bland M; Thompson M; Jahangiri M
    Interact Cardiovasc Thorac Surg; 2008 Feb; 7(1):37-40. PubMed ID: 18025061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation.
    Anné W; Willems R; Roskams T; Sergeant P; Herijgers P; Holemans P; Ector H; Heidbüchel H
    Cardiovasc Res; 2005 Sep; 67(4):655-66. PubMed ID: 15913581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast.
    Kim HJ; Park CI; Park BW; Lee HD; Jung WH
    Yonsei Med J; 2006 Jun; 47(3):333-42. PubMed ID: 16807982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.